This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schmelz, E. M. Articles by Majumdar, A. P.N. Search for Related Content PubMed PubMed Citation Articles by Schmelz, E. M. Articles by Majumdar, A. P.N.

Regression of Early and Intermediate Stages of Colon Cancer by Targeting Multiple Members of the EGFR Family with EGFR-Related Protein

¹ Department of Nutrition and Food Science, Wayne State University; ² Karmanos Cancer Institute, ³ Department of Pathology; and ⁴ Veterans Affairs Medical Center, ⁵ Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan

Requests for reprints: Eva M. Schmelz, Department of Human Nutrition, Foods and Excercise, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061. E-mail: eschmelz{at}vt.edu and Adhip P.N. Majumdar, VA Medical Center/Wayne State University, 4646 John R, Room-B4238, Detroit, MI 48220. Phone: 313-576-4460; Fax: 313-576-1112; E-mail: a.majumdar{at}wayne.edu.

A role of the epidermal growth factor receptor (EGFR) family has been suggested in colon cancer etiology, progression, and/or severity. Our recently identified pan-erbB inhibitor EGFR-related protein (ERRP) targets EGFRs by attenuating their activation and subsequent signaling leading to cellular growth inhibition. In the present study, we evaluated the therapeutic effectiveness of ERRP on early and intermediate stages of colon cancer by examining regression of chemically induced aberrant crypt foci (ACF) in the colon of CF1 mice and intestinal adenomas in APC^Min+/– (Min) mice. After formation of ACF or adenomas, the mice were injected (i.p.) with ERRP (50 µg/mouse) for 10 consecutive days. This treatment significantly reduced the number of ACF from 25.0 ± 3.0 (controls) to 14.9 ± 1.6 (ERRP-treated; P = 0.011) and also reduced their size (P < 0.01). In Min mice, ERRP caused the regression of adenomas throughout the small intestine (P < 0.05) and reduced their size (P < 0.001). This could partly be attributed to inhibition of proliferation and stimulation of apoptosis in the intestinal mucosa and was associated with decreased activation of several EGFR family members, suppression of downstream effector nuclear factor B and down-regulation of cyclooxygenase-2. ERRP-induced attenuation of EGFR activation could be due to increased sequestration of the ligand(s) by ERRP, rendering them unavailable for binding to and activation of the receptor. In conclusion, our data show that ERRP is effective in regressing both early and intermediate intestinal lesions and could be an effective therapeutic agent for colon cancer. [Cancer Res 2007;67(11):5389–96]